Gilead Profit Falls Short of Wall Street Expectations.

Published Date: 29 Apr 2023

As a result of lower-than-expected sales of the COVID-19 antiviral Veklury, Gilead Sciences on Thursday reported a lower-than-expected first-quarter profit, and its stock fell by more than 2%.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

TULSA Is Effective in Long-Term Prostate Cancer Control.

2.

AVD Chemo Regimen Shows Promise in Older Patients With HL

3.

Perioperative Nivolumab Boosts EFS Versus Neoadjuvant-Only Nivolumab in NSCLC

4.

Injecting PD-1 Drug Directly Into Oral Precancers Shrinks Lesions

5.

New Nanoparticles Can Destroy Undruggable Cancer Proteins


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot